Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $321.33 | 20 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $106.71 | 7 | $0 (2024) |
| Amgen Inc. | $79.66 | 5 | $0 (2024) |
| ABBVIE INC. | $46.01 | 2 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $43.11 | 3 | $0 (2022) |
| Novo Nordisk Inc | $32.10 | 2 | $0 (2024) |
| ModernaTX, Inc. | $13.74 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $108.22 | 6 | Amgen Inc. ($35.18) |
| 2023 | $157.92 | 10 | GlaxoSmithKline, LLC. ($79.34) |
| 2022 | $55.19 | 4 | Bayer HealthCare Pharmaceuticals Inc. ($43.11) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Obesity | ||||||
| 05/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Inflammation | ||||||
| 05/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: NEUROSCIENCE | ||||||
| 04/22/2024 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/16/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY, BEXSERO | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: VACCINES | ||||||
| 03/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Inflammation | ||||||
| 12/20/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Inflammation | ||||||
| 11/15/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: VACCINES | ||||||
| 10/08/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: RESPIRATORY | ||||||
| 09/06/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Inflammation | ||||||
| 06/14/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: VACCINES | ||||||
| 05/15/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX, BEXSERO | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: RESPIRATORY | ||||||
| 05/01/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Inflammation | ||||||
| 04/13/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: VACCINES | ||||||
| 03/03/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: Obesity | ||||||
| 11/21/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Cardio-renal | ||||||
| 11/08/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kyleena (Drug), Mirena | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Womens Health | ||||||
| 06/22/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: Cardio-renal | ||||||
| 06/09/2022 | GlaxoSmithKline, LLC. | BEXSERO (Biological), SHINGRIX, PEDIARIX | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 603 | 738 | $126,842 | $57,242 |
| 2022 | 16 | 502 | 641 | $104,153 | $46,266 |
| 2021 | 10 | 263 | 332 | $49,000 | $21,118 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 135 | 202 | $44,238 | $17,659 | 39.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 103 | 103 | $24,308 | $12,889 | 53.0% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 30 | 30 | $10,567 | $8,467 | 80.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $14,784 | $3,696 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 40 | $6,000 | $2,340 | 39.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 40 | $6,000 | $2,330 | 38.8% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 14 | 14 | $4,732 | $2,209 | 46.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 23 | 23 | $2,024 | $1,651 | 81.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 14 | $5,635 | $1,615 | 28.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 13 | 16 | $3,504 | $1,420 | 40.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 119 | 157 | $2,355 | $1,319 | 56.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 30 | 30 | $1,470 | $898.20 | 61.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 25 | 25 | $1,225 | $748.50 | 61.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 161 | $33,971 | $13,708 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 51 | 51 | $16,524 | $5,704 | 34.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 40 | 40 | $9,120 | $5,144 | 56.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 68 | $9,792 | $4,178 | 42.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 11 | 11 | $3,575 | $3,059 | 85.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 47 | $6,768 | $2,619 | 38.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 11 | 11 | $3,696 | $1,814 | 49.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 17 | $4,607 | $1,719 | 37.3% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 11 | 11 | $3,586 | $1,639 | 45.7% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 12 | 12 | $1,944 | $1,591 | 81.8% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 23 | 23 | $2,024 | $1,573 | 77.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 12 | $2,532 | $984.87 | 38.9% |
About Dr. Daniel Weisel, MD
Dr. Daniel Weisel, MD is a Family Medicine healthcare provider based in O Fallon, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2017. The National Provider Identifier (NPI) number assigned to this provider is 1629506522.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Weisel, MD has received a total of $321.33 in payments from pharmaceutical and medical device companies, with $108.22 received in 2024. These payments were reported across 20 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($321.33).
As a Medicare-enrolled provider, Weisel has provided services to 1,368 Medicare beneficiaries, totaling 1,711 services with total Medicare billing of $124,625. Data is available for 3 years (2021–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location O Fallon, MO
- Active Since 05/23/2017
- Last Updated 07/21/2022
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1629506522
Products in Payments
- Otezla (Drug) $79.66
- SHINGRIX (Biological) $61.63
- VRAYLAR (Drug) $46.01
- AREXVY (Drug) $33.00
- Wegovy (Drug) $32.10
- Kerendia (Drug) $29.83
- Moderna Covid-19 Vaccine (Biological) $13.74
- Kyleena (Drug) $13.28
- BEXSERO (Biological) $12.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in O Fallon
Dr. Nell Hennon, D.o, D.O
Family Medicine — Payments: $13,619
Thomas Wright, Md, MD
Family Medicine — Payments: $11,514
Robert Thain, Md, MD
Family Medicine — Payments: $10,821
Dr. Steven Taylor, M.d, M.D
Family Medicine — Payments: $9,293
Caitlin Rogers, Do, DO
Family Medicine — Payments: $7,866
Rema Sanghavi, D.o, D.O
Family Medicine — Payments: $5,773